- Identity and purity checked by HPLC; per-lot COA on request
- Certificate of analysis tied to your lot number
- Tracked EU delivery, dispatched the next working day
Orforglipron (Oral GLP-1 Research Compound)
Oral, non-peptide GLP-1 receptor agonist in bottles of 30 research capsules
In stock2 formats available
€97Range €97 – €165
This listing is currently unavailable. Contact us and we will tell you when it is back or suggest an equivalent.
Ask about this listing or request its COA- FormOral capsules in a sealed bottle with desiccant
- Research areasIncretin receptor pharmacology, glucose-dependent insulin secretion, gastric emptying, food-intake and body-composition models
For laboratory research use only. Sold exclusively for in-vitro laboratory research by qualified professionals. Not for human or veterinary use, and not a medicine, food, cosmetic or dietary supplement. Terms and Conditions
Overview
Key facts
Orforglipron activates the glucagon-like peptide-1 receptor, yet it is not a peptide — it is a small, drug-like molecule.
- Purity
- HPLC tested for identity and purity; lot-matched COA available
- Form
- Oral capsules in a sealed bottle with desiccant
- Storage
- Room temperature in the sealed bottle, protected from light, heat and humidity
- Available sizes
- 3 mg · 30 capsules · 12 mg · 30 capsules
For research use only. Not for human consumption.
Orforglipron activates the glucagon-like peptide-1 receptor, yet it is not a peptide — it is a small, drug-like molecule. That fact alone accounts for the research interest: all the heavily studied incretin agents that came before it (tirzepatide, liraglutide, semaglutide) are peptides, and peptides are digested and poorly absorbed, which limits oral use. Orforglipron engages the receptor the way a conventional small-molecule drug would, so it is investigated as an oral compound that needs no absorption enhancer like SNAC.
How it signals is the other reason it appears in comparative studies. Published data characterise it as a biased partial agonist: it favours Gs-driven cAMP production and recruits less beta-arrestin than peptide agonists, and weaker arrestin recruitment goes hand in hand with slower receptor internalisation and desensitisation. Whether that alters the downstream phenotype is exactly what such comparisons aim to find out. In the literature it also appears as LY3502970 and OWL833 — search under both when compiling references. We supply 3 mg and 12 mg capsules, thirty per bottle with a desiccant, stored at room temperature; no cold chain or reconstitution is needed, as you would expect for a small organic molecule rather than a peptide.
Specifications
Supply & purity
- Form
- Oral capsules in a sealed bottle with desiccant
- Purity
- HPLC tested for identity and purity; lot-matched COA available
- Available sizes
- 3 mg × 30 capsules, 12 mg × 30 capsules
Additional detail
- Compound class
- Non-peptide small-molecule GLP-1 receptor agonist
- Molecular target
- Glucagon-like peptide-1 receptor (GLP-1R), a class B GPCR
- Signalling profile
- Biased partial agonism — cAMP/Gs-favoured with reduced β-arrestin recruitment
- Structural note
- Small organic molecule; no amino acid sequence and no peptide backbone
- Also known as
- LY3502970, OWL833
- Delivery note
- Studied as an oral compound without SNAC or other peptide absorption enhancers
- Research areas
- Incretin receptor pharmacology, glucose-dependent insulin secretion, gastric emptying, food-intake and body-composition models
- Regulatory status
- Investigational compound; not supplied as an approved medicine
- Reconstitution
- None required — supplied in finished capsule form
- Storage
- Room temperature in the sealed bottle, protected from light, heat and humidity
Questions about Orforglipron (Oral GLP-1 Research Compound)
What kind of compound is orforglipron?
A small, non-peptide molecule that switches on the GLP-1 receptor. Investigated as an oral incretin agonist, it serves in research as the small-molecule comparator to peptide GLP-1 analogues like tirzepatide and semaglutide.
In what way is it different from oral semaglutide?
Oral semaglutide is a peptide that relies on the absorption enhancer SNAC to get through the gut; orforglipron contains no peptide and is studied as an ordinary oral small molecule. Their receptor signalling also differs — orforglipron is described as a biased partial agonist.
How is its purity confirmed?
HPLC testing checks identity and purity for every lot, and the lot's Certificate of Analysis can be viewed on this page before ordering. It records the methods used and the results for the specific lot you receive.
Which strengths are offered?
Bottles of 30 capsules at either 3 mg or 12 mg. Two strengths let labs set up concentration comparisons without weighing bulk powder, and both come in sealed bottles containing a desiccant.
How should the capsules be kept?
At room temperature in the sealed bottle, away from light, heat and humidity, with the desiccant left in. Don't move capsules into unlabelled containers, and note lot number and opening date to keep the material traceable.
Related
